Cost effectiveness of long-acting risperidone: What can pharmacoeconomic models teach us? Lieven Annemans Introduction 17 September 2012 Pages: 1 - 2
Pharmacoeconomics of long-acting risperidone: Results and validity of cost-effectiveness models Alan Haycox Review Article 17 September 2012 Pages: 3 - 16
Modelling the treated course of schizophrenia: Development of a discrete event simulation model Bart M. S. HeegErik BuskensBen A. van Hout Original Research Article 17 September 2012 Pages: 17 - 33
Long-acting risperidone compared with oral olanzapine and haloperidol depot in schizophrenia: a Belgian cost-effectiveness analysis Diana De GraeveAnn SmetJoseph Peuskens Original Research Article 17 September 2012 Pages: 35 - 47
Costs and effects of long-acting risperidone compared with oral atypical and conventional depot formulations in Germany Gerd LauxBart M. S. HeegAngelika Mehnert Original Research Article 17 September 2012 Pages: 49 - 61
Modelling the impact of compliance on the costs and effects of long-acting risperidone in Canada P. S. ChueBart M. S. HeegBen A. van Hout Original Research Article 17 September 2012 Pages: 62 - 74
Cost effectiveness of long-acting risperidone injection versus alternative antipsychotic agents in patients with schizophrenia in the USA Natalie Christine EdwardsJulie C. LocklearRonald J. Diamond Original Research Article 17 September 2012 Pages: 75 - 89
